WO2005077897A1 - Substituted azetidine compounds, their preparation and use as medicaments - Google Patents

Substituted azetidine compounds, their preparation and use as medicaments Download PDF

Info

Publication number
WO2005077897A1
WO2005077897A1 PCT/EP2005/001658 EP2005001658W WO2005077897A1 WO 2005077897 A1 WO2005077897 A1 WO 2005077897A1 EP 2005001658 W EP2005001658 W EP 2005001658W WO 2005077897 A1 WO2005077897 A1 WO 2005077897A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
optionally
substituted
mono
linear
Prior art date
Application number
PCT/EP2005/001658
Other languages
English (en)
French (fr)
Inventor
Rosa Cuberes Altisen
Jordi Frigola Constansa
Bonifacio Gutierrez Silva
Original Assignee
Laboratorios Del Dr. Esteve S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200400379A external-priority patent/ES2244314B1/es
Application filed by Laboratorios Del Dr. Esteve S.A. filed Critical Laboratorios Del Dr. Esteve S.A.
Priority to RU2006133258/04A priority Critical patent/RU2006133258A/ru
Priority to CA002556565A priority patent/CA2556565A1/en
Priority to BRPI0507801-6A priority patent/BRPI0507801A/pt
Priority to JP2006553539A priority patent/JP2007522255A/ja
Priority to AU2005212835A priority patent/AU2005212835A1/en
Priority to EP05715383A priority patent/EP1718609A1/de
Publication of WO2005077897A1 publication Critical patent/WO2005077897A1/en
Priority to IL177456A priority patent/IL177456A0/en
Priority to US11/505,463 priority patent/US20070066587A1/en
Priority to NO20064078A priority patent/NO20064078L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
  • Cannabinoids are compounds, which are derived from the cannabis sativa plant which is commonly known as marijuana.
  • the most active chemical compound of the naturally occurring cannabinoids is tetrahydrocannabinol (THC), particularly ⁇ 9 -THC.
  • cannabinoids as well as their synthetic analogues promote their physiological effects via binding to specific G-coupled receptors, the so-called cannabinoid-receptors.
  • CB ⁇ and CB 2 are involved in a variety of physiological or pathophysiological processes in humans and animals, e.g. processes related to the central nervous system, immune system, cardiovascular system, endocrinous system, respiratory system, the gastrointestinal tract or to reproduction, as described for example, in Hollister, Pharm. Rev. 38, 1986, 1-20; Reny and Singha, Prog. Drug. Res., 36, 71-114, 1991; Consroe and Sandyk, in Marijuana/Cannabinoids, Neurobiology and Neurophysiology, 459, Murphy L and Barthe A. Eds., CRC Press, 1992.
  • medicaments preferably in medicaments for the modulation of Cannabinoid receptors, particularly Cannabinoid 1 (CB-i) receptors.
  • said medicaments should be suitable for the prophylaxis and/or treatment of disorders related to the central nervous system, the immune system, the cardiovascular system, the endocrinous system, the respiratory system, the gastrointestinal tract or reproduction in humans and/or animals.
  • the present invention relates to substituted Azetidine compounds of general formula I,
  • R 1 represents an optionally at least mono-substituted phenyl group
  • R 2 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system
  • R 3 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted
  • R 4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched alkyl group, or an optionally at least mono-substituted aryl group,
  • R 5 represents an -O-SO 2 -R 6 -moiety, an -NH-CO-R 7 -moiety, an -Nh -moiety, an - NH-SO 2 -R 8 moiety, an -NR 9 -SO 2 -R 10 -moiety or an -O-CO-R 11 -moiety,
  • R 6 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
  • R 7 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group
  • R 8 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may
  • R 9 represents an -S0 2 -R 12 -moiety, a -CO-R 13 -moiety, a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or branched alkylene group and/or bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via an alkylene group,
  • R 10 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group
  • R 11 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at
  • R 12 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
  • R 13 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/
  • a mono- or polycyclic ring-system means a mono- or polycyclic hydrocarbon ring-system that may be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, i.e. it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono- or polycyclic ring system may contain one or more, e.g. 1 , 2 or 3, heteroatoms as ring members, which may be identical or different and which can preferably be selected from the group consisting of N, O, S and P, more preferably be selected from the group consisting of N, O and S. Preferably the polycyclic ring-system may comprise two rings that are condensed.
  • the rings of the mono- or polycyclic ring-sytem are preferably 5- or 6-membered.
  • condensed means that a ring or ring- system is attached to another ring or ring-system, whereby the terms “annulated” or “annelated” are also used by those skilled in the art to designate this kind of attachment.
  • each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C ⁇ .
  • residues R 2 , R 3 and R 6 -R 13 represents or comprises a cycloaliphatic group, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O and S.
  • a cycloaliphatic group may contain 1 , 2 or 3 heteroatoms independently selected from the group consisting of N, O and S.
  • Suitable saturated or unsaturated, optionally at least heteroatom as ring member containing, optionally at least mono-substituted cycloaliphatic groups may preferably be selected from the group consisting of Cyclopropyl, Cyclobutyl, Cyclopentyl, Cyclohexyl, Cycloheptyl, Cyclooctyl, Cyclopentenyl, Cyclohexenyl, Cycloheptenyl, Cyclooctenyl, Pyrrolidinyl, Piperidinyl, Piperazinyl, Homo-Piperazinyl and Morpholinyl.
  • each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C-i- 4 -alkoxy, branched or unbranched C ⁇ -alkyl, branched or unbranched C 1 - 4 - perfluoroalkoxy, branched or unbranched C ⁇ - 4 -perfluoroalkyl, amino, carboxy, oxo, amido, cyano, nitro, -SO 2 NH 2 , -CO-C- M -alkyl, -SO-C ⁇ -alkyl, -SO 2 -d ⁇ -alkyl, -NH- SO 2 -C ⁇ - 4 -alkyl , wherein the C
  • each of the substituents may be independently selected from the group consisting of a halogen atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ . 6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C-
  • 6 -alkyl group a cyano group, a carboxy group, a - CO-O-C- ⁇ - 6 -alkyl group, a -CO-NR A R B - moiety, a -CO-NH-NR c R D -moiety, an -S-d-e- alkyl group, an -SO-d. 6 -alkyl group, an -S0 2 -C ⁇ . 6 -alkyl group, a -C ⁇ . 6 -alkylene-S-C ⁇ . 6 - alkyl group, a -C ⁇ . 6 -alkylene-SO-C ⁇ .
  • R A , R B identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R A and R B together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C-i-e alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R c , R D identical or different, represent a hydrogen atom, a C ⁇ - 6 -alkyl group, a -CO-O-C ⁇ - 6 -alkyl group, a C 3 - 8 -cycloalkyl group, a C ⁇ - 6 -alkylene-C 3 .
  • R E , R F identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R E and R F together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different Ci- ⁇ alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member.
  • Preferred aryl groups which may optionally be at least mono-substituted, are phenyl and naphthyl. If one or more of the residues R 2 , R 3 and R 6 -R 13 represents or comprises a heteroaryl group, which is substituted by one or more, e.g.
  • each of the substituents may be independently selected from the group consisting of a halogen atom, a linear or branched Ci- 6 -alkyl group, a linear or branched C-i- 6 alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C ⁇ . 6 -alkyl group, a cyano group, a carboxy group, a - CO-O-d.
  • 6 -alkyl group a -CO-NR A R B - moiety, a -CO-NH-NR c R D -moiety, an -S-d_ 6 - alkyl group, an -SO-d-6-alkyl group, an -SO 2 -C ⁇ . ⁇ -alkyl group, a -C ⁇ . 6 -alkylene-S-C ⁇ . 6 - alkyl group, a -C ⁇ . 6 -alkylene-SO-C ⁇ . 6 -alkyl group, a -C ⁇ - 6 -alkylene-SO 2 -C ⁇ . 6 -alkyl group, a d- 6 -alkyl group substituted by one or more hydroxy groups and a -d- ⁇ - alkylene-NR E R F group,
  • R A , R B identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R A and R B together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C ⁇ _ 6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R c , R D identical or different, represent a hydrogen atom, a C ⁇ . 6 -alkyl group, a -CO-O-d- 6 -alkyl group, a C 3 . 8 -cycloalkyl group, a C ⁇ . 6 -alkylene-C 3 . 8 -cycloalkyl group, C ⁇ - 6 -alkylene-0-C ⁇ - 6 -alkyl group or a C ⁇ .
  • 6 -alkyl group substituted with one or more hydroxy groups, or R c , R D together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of d- 6 alkyl group, a -CO-Ci- 6 -alkyl group, a -CO-O- Ci- ⁇ -alkyl group, a - CO-NH- C ⁇ _ 6 -alkyl group, a -CS-NH- C ⁇ . 6 -alkyl group, an oxo group, a C ⁇ .
  • 6 -alkyl group substituted with one or more hydroxy groups, a C ⁇ . 6 -alkylene-O-C ⁇ . 6 -alkyl group and a -CO-NH 2 group and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member, and
  • R E , R F identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R E and R F together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different C ⁇ _ 6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • heteroatoms which are present as ring members in the heteroaryl radical, may, unless defined otherwise, independently be selected from the group consisting of nitrogen, oxygen and sulphur.
  • a heteroaryl radical may contain 1, 2 or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulphur.
  • Suitable heteroaryl groups may preferably be selected from the group consisting of thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrimidinyl, pyrazinyl, indolyl, chinolinyl, isochinolinyl, benzo[1 ,2,5]- thiodiazolyl, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2,1-b]thiazolyl and pyrazolyl, more preferably be selected from the group consisting of thienyl-, benzo[1,2,5]-thiodiazolyl, benzo[b]thiophenyl, imidazo[2,1-b]thiazolyl and pyrazolyl.
  • each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C ⁇ - 4 -alkoxy, branched or unbranched Ci- 4 -perfluoroalkoxy, branched or unbranched d- 4 -perfluoroalkyl, amino, carboxy, amido, cyano, nitro, -SO 2 NH 2 , -CO-d- 4 -alkyl, -SO-C ⁇ .
  • d. 4 -alkyl may in each case be branched or unbranched, and a phenyl group, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF 3 and a phenyl group.
  • Preferred linear or branched, saturated or unsaturated aliphatic groups which may be substituted by one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethinyl, propenyl, propinyl, butenyl and butinyl.
  • any of the residues R 3 and R 6 -R 13 comprises a linear or branched alkylene group
  • said alkylene group may preferably be selected from the group consisting of methylene (-(CH 2 )-), ethylene (-(CH 2 ) 2 -), n-propylene (-(CH 2 ) -), isopropylene (-(C(CH )2-), n-butylene (-(CH 2 ) 4 -), n-pentylene (-(CH 2 ) 5 -), n-hexylene ( -(CH 2 ) 6 -), n-heptylene (-(CH 2 ) 7 -), n-octylene (-(CH 2 ) 8 -), n-nonylene( -(CH 2 ) 9 -) and n-decylene (-(CH 2 ) ⁇ 0 -), more preferably from the group consisting of (-(CH 2 )-), ethylene (-(
  • R 1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched Ci- 6 -alkyl group, a linear or branched C- ⁇ - 6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C ⁇ .
  • 6 -alkyl group a cyano group, a carboxy group, a -CO-O-C ⁇ - 6 -alkyl group, a -CO-NR A R B - moiety, a -CO-NH-NR c R D -moiety, an -S-C ⁇ . 6 -alkyl group, an -SO-C ⁇ . 6 -alkyl group, an -S ⁇ 2 -C ⁇ - 6 -alkyl group, a -C ⁇ _6-alkylene-S-C ⁇ -6-alkyl group, a -C ⁇ . 6 -alkylene-SO-C ⁇ - 6 - alkyl group, a -C ⁇ . 6 -alkylene-SO 2 -C ⁇ - 6 -alkyl group, a Ci- ⁇ -alkyl group substituted by one or more hydroxy groups and a -C ⁇ . 6 -alkylene-NR E R F group,
  • R A , R B identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R A and R B together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C 1 - 6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R c , R D identical or different, represent a hydrogen atom, a C ⁇ . 6 -alkyl group, a -CO-O-Ci- 6 -alkyl group, a C 3 . 8 -cycloalkyl group, a C ⁇ - 6 -alkylene-C 3 . 8 -cycloalkyl group, C-
  • R E , R F identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R E and R F together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different C-i-e alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R 1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ _ 6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group,
  • R 1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, most preferably R 1 represents a phenyl group, which is substituted by a chlorine atom in the 4-position,
  • R 2 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
  • R 2 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least heteroatom as ring member containing C 3 . 8 cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system,
  • R 2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ _ 6 alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a - CO-Ci- 6 -alkyl group, a cyano group, a carboxy group, a -CO-O-C ⁇ .6-alkyl group, a - CO-NR A R B - moiety, a -CO-NH-NR c R D -moiety, an -S-d.
  • substituents independently selected from the group consisting of a halogen atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ _ 6 alcoxy group, a formy
  • 6 -alkyl group an -SO-C 1 - 6 - alkyl group, an -SO 2 -C ⁇ . 6 -alkyl group, a -C ⁇ . 6 -alkylene-S-C ⁇ - 6 -alkyl group, a -d. 6 - alkylene-SO-C ⁇ - 6 -alkyl group, a -C ⁇ - 6 -alkylene-SO 2 -C ⁇ _ 6 -alkyl group, a C ⁇ . 6 -alkyl group substituted by one or more hydroxy groups and a -d. 6 -alkylene-NR E R F group,
  • R A , R B identical or different, represent hydrogen or a C ⁇ - 6 -alkyl group, or R A and R B together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C ⁇ _ 6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R c , R D identical or different, represent a hydrogen atom, a d- 6 -alkyl group, a -CO-O-Ci_ 6 -alkyl group, a C 3 . 8 -cycloalkyl group, a C ⁇ - 6 -alkylene-C 3 - 8 -cycloalkyl group, C ⁇ - 6 -alkylene-O-C ⁇ - 6 -alkyl group or a C ⁇ .
  • 6 -alkyl group substituted with one or more hydroxy groups, or R c , R D together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of C 1 . 6 alkyl group, a -CO-C ⁇ . 6 -alkyl group, a -CO-O- C ⁇ _ 6 -alkyl group, a - CO-NH- Ci- 6 -alkyl group, a -CS-NH- C ⁇ profession 6 -alkyl group, an oxo group, a C ⁇ .
  • R E , R F identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R ⁇ and R F together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different C-j- ⁇ alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R 2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group,
  • R 2 represents a phenyl group, which is substituted by a chlorine atom in the 4-position
  • R 1 and R 3 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
  • R 3 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C ⁇ _ ⁇ o-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 .
  • R 3 represents a linear or branched, optionally at least mono-substituted C ⁇ - 10 -alkyl group, or an optionally at least mono-substituted, 5- or 6- membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched C ⁇ _ 6 -alkylene group, more preferably R 3 represents a linear or branched, unsubstituted C ⁇ - ⁇ 0 -alkyl group, most preferably R 3 represents a methyl group, and R 1 , R 2 and R 4 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof,
  • R 4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched C ⁇ - ⁇ 0 -alkyl group, or an optionally at least mono-substituted, 5- or 6- membered aryl group
  • R 4 represents a hydrogen atom, a linear or branched Ci- 3 -alkyl group, or an optionally at least mono-substituted phenyl group, more preferably R 4 represents a hydrogen atom or a linear or branched C ⁇ _ 3 -alkyl group, most preferably R 4 represents a hydrogen atom
  • R 1 -R 3 and R 5 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers,
  • R 5 represents an -O-SO 2 -R 6 -moiety, an -NH-CO-R 7 -moiety, an -NH 2 -moiety, an -NH- SO 2 -R 8 moiety or an -NR 9 -SO 2 -R 10 -moiety
  • R 5 represents an -O-SO 2 -R 6 - moiety, an -NH-S0 2 -R 8 moiety or an -NR 9 -SO 2 -R 10 -moiety
  • R 1 -R 4 and R 6 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof,
  • R 6 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C 1 - 10 aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 . 8 - cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched C ⁇ .
  • R 6 represents an optionally at least mono-substituted C 3 -s-cycloaliphatic group or an optionally at least mono-substituted phenyl group, wherein the respective substituents are independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ - ⁇ alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group, more preferably R 6 represents a pheny
  • R 7 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C ⁇ - ⁇ o-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 . 8 - cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched C ⁇ .
  • R 7 represents a linear or branched, optionally at least mono-substituted C ⁇ - 5 -alkyl group, a saturated, optionally at least mono-substituted C 5tician 6 -cycloaliphatic group, or an optionally at least mono-substituted phenyl group, wherein in each case the substituents are independently from one another selected from the group consisting of group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, and R 1 -R 6 and R 8 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers
  • R 8 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C ⁇ - ⁇ o-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 .
  • R 8 represents a linear or branched C ⁇ - 10 -alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 5 .
  • R 8 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a
  • R 9 represents an -SO 2 -R 2 -moiety, a -CO-R 13 -moiety, a linear or branched, saturated or unsaturated, optionally at least mono-substituted d-10 aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least heteroatom as ring member containing C3-8 cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded by a linear or branched C 1 .
  • R 9 represents an -SO 2 -R 12 -moiety, a linear or branched C 1 - 10 alkyl group, or an optionally at least mono-substituted phenyl group, which may be bonded via a C ⁇ _ 2 alkylene group, more preferably R 9 represents an - S0 2 -R 12 -moiety, a linear or branched d_ 3 alkyl group, or a phenyl group, which may be bonded via a C ⁇ _ 2 alkylene group and/or substituted with one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom and a bromine atom, and R 1 -R 8 and R 10 -R 13 have the meaning given above optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably en
  • R 10 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C ⁇ . 10 -aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 3 _ 8 -cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Ci- 10 -alkylene group and/or which may be bridged by a linear or branched C ⁇ _ 5 -alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Ci-10-alkylene group, preferably R 10 represents a linear or branched
  • R 10 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via
  • R 11 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C ⁇ - ⁇ o-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 - 8 - cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged C ⁇ - ⁇ o-alkylene group and/or which may be bridged by a linear or branched C ⁇ - 5 -alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched C ⁇ _ ⁇ o-alkylene group, preferably R 11 represents a -linear or-branched C
  • ring member containing C 5 - 6 - cycloaliphatic group which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged C ⁇ .
  • R 11 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C ⁇ - 3 -alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H- pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1
  • R 12 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted Ci- 10 -aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 .
  • R 12 represents a linear or branched C ⁇ _ ⁇ o-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 5 .
  • R 12 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a d- 3 -alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H- pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1
  • R 13 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C 1 - 10 - aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 3 - 8 -cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged C ⁇ _ ⁇ o-alkylene group and/or which may be bridged by a linear or branched C ⁇ - 5 -alkylene group, or an optionally at least mono- substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched C- M o-alkylene group, preferably R 13 represents a linear or branched C-MO
  • R 13 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono- substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C ⁇
  • R 7 represents a linear or branched C 1 - 5 alkyl group, said alkyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C 1 .
  • -R 8 represents a linear or branched C 1 . 5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C 1 -6 alkyl. linear or branched C ⁇ .
  • phenyl optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C ⁇ _ 6 alkyl and linear or branched C 1 - 6 - alcoxy
  • phenoxy optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d- 6 alkyl and linear or branched C ⁇ .
  • R 10 represents a linear or branched C 1 - 5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1- 6 alkyl, linear or branched d-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C ⁇ _ 6 alkyl and linear or branched d.
  • R 11 represents a linear or branched C 1 - 5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
  • substituents independently selected from the group consisting of F, Cl, Br, linear or branched C 1 - 6 alkyl, linear or branched d- 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C 1 - 6 alkyl and linear or branched C 1 - 6 - alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C 1 . 6 alkyl and linear or branched d.
  • R 12 represents a linear or branched C 1 - 5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ - 6 alkyl, linear or branched C 1 - 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C 1 - 6 alkyl and linear or branched C 1 - 6 - alcoxy), phenoxy
  • R 13 represents a linear or branched C1. 5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
  • substituents independently selected from the group consisting of F, Cl, Br, linear or branched C 1 .6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C 1 - 6 alkyl and linear or branched d.
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, especially to compounds of the following formula lb,
  • X represents a halogen atom, preferably a chlorine atom
  • alkyl group said alkyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C- ⁇ - 6 alcoxy, -CF 3 and -OCF 3 ; a cyclopentyl or cyclohexyl group, said cyclopentyl or cyclohexyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C 1 - 6 alcoxy, -CF 3 and -OCF 3 ; or a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ . 6 alkyl, linear or branched C
  • R 8 represents a linear or branched C 1 -5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1, 2, 3,
  • R 10 represents a linear or branched C 1 .5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C-i-e alkyl, linear or branched C 1 - 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d_ 6 alkyl and linear or branched d.
  • R 11 represents a linear or branched C 1 - 5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
  • substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ - 6 alkyl, linear or branched C 1 - 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d_ 6 alkyl and linear or branched C 1 - 6 - alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1- 6 alkyl and linear or branched d.
  • R 12 represents a linear or branched C1.
  • an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
  • substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ . 6 alkyl, linear or branched C ⁇ . 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C ⁇ _ 6 alkyl and linear or branched C ⁇ - 6 - alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d- 6 alkyl and linear or branched d.
  • R 13 represents a linear or branched C1. 5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ .
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
  • R 1 represents a phenyl group, which is mono-substituted with a halogen atom, preferably a chlorine atom, in the 4-position of the phenyl ring,
  • R 2 represents a phenyl group, which is mono-substituted with a halogen atom, preferably a chlorine atom, in the 4-position of the phenyl ring,
  • R 3 represents a linear or branched, unsubstituted C ⁇ _ 6 alkyl group, preferably a methyl group,
  • R 4 represents a hydrogen atom
  • R 5 represents an -O-SO 2 -R 6 -moiety, an -NH-CO-R 7 -moiety, an -NH 2 -moiety, an NH-SO 2 -R 8 moiety, or an -NR 9 -SO 2 -R 10 -moiety
  • R 6 represents a phenyl ring, which is optionally substituted with one or more halogen atoms, preferably one or more fluorine and/or one or more chlorine atoms,
  • R 7 represents a linear or branched C 1 -5 alkyl group, a linear or branched C 1 - 5 alkyl group, which is at least partially fluorinated, a C 3 . 8 cycloalkyl group, or a phenyl group, which is optionally substituted with one or more halogen atoms, preferably one or more fluorine atoms,
  • R 8 represents a linear or branched C 1 . 5 alkyl group
  • a phenyl group which is optionally substituted with one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, an unsubstituted phenyl group, a formyl group, a methylsulfonyl group, a benzyl group and a phenoxy group, which is optionally mono-substituted by a bromine atom in its 4-position,
  • a naphthyl group which may be bonded via a methylene or ethylene group
  • Benzo[b]thiophene group which is optionally substituted with one or more methyl groups and/or one or more chlorine atoms,
  • a pyrazole group which is optionally substituted with one or more substituents independently selected from the group consisting of a methyl group, an ethyl group and a phenyl group,
  • thienyl group a furyl group, a.2,1,3-Benzothiadiazole group, a 7,7-Dimethyl-2-oxo- bicyclo-[2.2.1]-hept-1-yl group, or a benzyl group,
  • R 9 represents a C 1 . 5 alkyl group, preferably a methyl group, a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms, a benzyl group, wherein the ring is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms, or a -S0 2 -R 12 -moiety,
  • R 10 represents a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms,
  • R 12 represents a C 1 . 5 alkyl group, preferably a methyl group, or a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms,
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
  • substituted azetidine compounds of general formula I given above selected from the group consisting of
  • the present invention provides a process for the preparation of substituted azetidine compounds of general formula I given above and corresponding stereoisomers thereof, according to which at least one compound of general formula
  • R 1 to R 4 have the meaning given above, is reacted with at least one compound of general formula X 1 -SO 2 -R 6 or X 2 -CO-R 11 , wherein R 6 and R 11 have the meaning given above and X 1 and X 2 represent suitable leaving groups, in a suitable reaction medium, optionally in the presence of at least one base, to yield at least one compound of general formula I given above, wherein R 5 represents an -O-S0 2 -R 6 - moiety or an -0-CO-R 11 -moiety, and optionally purifying and/or optionally isolating said compound(s),
  • R 5 represents an -O-SO 2 -R 6 or an -O-CO-R 11 moiety
  • ammonia is reacted with ammonia, to yield a compound of general formula I, wherein R 5 represents an -NH 2 -moiety, and optionally purifying and/or optionally isolating said compound(s),
  • R 5 represents an -NH 2 -moiety
  • R 7 , R 8 and R 10 have the meaning given above and X 3 , X 4 and X 5 are suitable leaving groups, in a reaction medium, optionally in the presence of at least one base, to yield a compound of general formula I given above, wherein R 5 represents an -NH-CO-R 7 -moiety, an -NH-SO 2 -R 8 -moiety or an - NR 9 -S ⁇ 2 -R 10 -moiety with R 9 representing a hydrogen atom, and optionally purifying and/or optionally isolating said compound(s),
  • R 5 represents an -NR 9 -SO 2 -R 10 -moiety with R 9 representing a hydrogen atom is reacted with at least one compound of general formula X 6 -R 9 , wherein R 9 has the meaning given above except for a hydrogen atom and X 6 is a leaving group, to yield at least one compound of general formula I given above, wherein R 5 represents an -NR 9 -SO 2 -R 10 -moiety, and optionally purifying and/or optionally isolating said compound(s),
  • R 4 represents a hydrogen atom and R 1 -R 3 have the meaning given above, is oxidized to yield at least one compound of general formula IV,
  • R 1 -R 3 have the meaning given above, which is optionally purified and/or optionally isolated, and reacted with at least one compound of general formula R 5a H, wherein R 5a represents an -NH 2 -moiety or an -NHR 9 -moiety, wherein R 9 has the meaning given above, the resulting compound is optionally purified and/or optionally isolated and optionally reacted with at least one compound of general formula X 3 -CO-R 7 , X 4 -SO 2 -R 8 or X 5 -SO 2 -R 10 , wherein R 7 , R 8 and R 10 have the meaning given above and X 3 , X 4 and X 5 represent a leaving group, in a reaction medium, optionally in the presence of at least one base, to yield a compound of general formula I given above, wherein R 5 represents an -NH 2 -moiety, an -NH-CO-R 7 -moiety, an -NH-SO2- R 8 -m
  • step (a) according to scheme 1 is carried out in one or more organic solvents as reaction medium.
  • Suitable solvents include but are not limited to halogenated, preferably chlorinated, organic solvents such as dichloromethane or chloroforme and linear or cyclic ethers, such as tetrahydrofurane, 1 ,4-dioxane, or 1,1- dimethoxyethane.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range. The optimum reaction temperature and duration of reaction for a given reaction may be determined by conventional methods known to those skilled in the art.
  • Preferred reaction temperatures are 0-30 °C, preferably 15-25 °C. Suitable reaction times may vary from approximately 10 minutes to 3 days.
  • Suitable bases for use in step (a) include organic bases such as triethylamine or pyridine as well as inorganic bases such as sodium hydroxide or potassium hydroxide. Mixtures of one or more organic bases and/or one or more inorganic bases may also be used.
  • the leaving groups X 1 and X 2 may be of any type known to those skilled in the art for this type of reaction.
  • the leaving group is a halogen atom, more preferably a chlorine or bromine atom.
  • Suitable reaction media for the reaction with ammonia according to step (b) of scheme 1 include, for example, alcohols such as methanol, ethanol, isopropanol or mixtures of at least two of these alcohols.
  • the ammonia is preferably added as a concentrated, preferably aqueous solution.
  • Reaction temperature, pressure as well as the duration of the reaction may vary over a broad range.
  • the optimum conditions may be determined by conventional methods known to those skilled in the art.
  • Preferred reaction temperatures range from ambient temperature, i.e. approximately 15-25 °C to the boiling point of the reaction medium. Suitable reaction times may vary, for example from approximately 10 minutes to 3 days. Obviously the reaction may also be carried out in a reactor at elevated temperatures and pressure.
  • Preferably compounds of general formula I, wherein R 5 represents a -0-S0 2 -R 6 -moiety with R 6 representing a methyl group, are used in step (b).
  • the reaction steps (c) and (d) according to scheme 1 may also be carried out under conventional conditions known to those skilled in the art.
  • a suitable reaction medium used for these reaction steps is preferably comprises one or more organic solvents.
  • Suitable solvents include but are not limited to halogenated, preferably chlorinated, organic solvents such as dichloromethane or chloroforme and linear or cyclic ethers, such as tetrahydrofurane, 1,4-dioxane, or 1,1-dimethoxyethane.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range. The optimum conditions for a given reaction may be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are 0-30 °C, preferably 15-25 °C. Suitable reaction times vary, e.g. from approximately 10 minutes to 3 days.
  • Suitable bases that may be present during reaction steps (c) and (d) include organic bases such as triethylamine or pyridine as well as inorganic bases such as sodium hydroxide or potassium hydroxide. Mixtures of one or more organic bases and/or one or more inorganic bases may also be used.
  • the leaving groups X 3 , X 4 , X 5 and X 6 may be of any type known to those skilled in the art for this type of reaction.
  • the leaving group is a halogen atom, more preferably a chlorine or bromine atom.
  • step (e) of scheme 1 may preferably be carried out according to the literature publications of Katritzky et al., J. Heterocycl. Chem., 1994, 271-275; P.R. Dave et al., J. Org. Chem., 1996, 61(16), 5453, Synlett. 1991, (11), 783-784 and Axenrod et al., Tetrahedron Lett., 1993, 6677-6680.
  • the respective descriptions are hereby incorporated by reference and form part of the present disclosure.
  • step (f) according to scheme 1 is carried out in one or more organic solvents as reaction medium such as chlorinated, organic solvents like dichloromethane or chloroforme and preferably in the presence of sodium triacetoxyborohydride and acetic acid, or in the presence of H 2 and an alcohol such as methanol and/or ethanol as a reaction medium.
  • organic solvents as reaction medium such as chlorinated, organic solvents like dichloromethane or chloroforme and preferably in the presence of sodium triacetoxyborohydride and acetic acid, or in the presence of H 2 and an alcohol such as methanol and/or ethanol as a reaction medium.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range.
  • the optimum reaction temperature and duration of reaction for a given reaction may be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are 0-30 °C, preferably 15-25 °C.
  • the substituents R 1 -R 4 have the same meaning as definied above and X represents a halogen atom, preferably a bromine or chlorine atom.
  • X represents a halogen atom, preferably a bromine or chlorine atom.
  • the substituted hydroxy-alkenylene compounds used as a starting material for reaction steps A and A1 according to scheme 2 are commercially available and/or may be prepared according to methods well known to those skilled in the art, e.g. by reduction of the corresponding carbonyl compound with a suitable reducing agent such as aluminium lithium hydride, sodium borohydride or catalysed hydrogenation as described, for example, in Catalysis Letters, 1999, 62(2-4), 175-177; Tetrahedron, 1984, 40(7), 1195-1198; J. Org.
  • halogenenated alkenylene compounds used as starting material for reaction step B and B1 are commercially available and/or may be prepared from the corresponding hydroxy-alkenylene compounds using a suitable halogenation agent such as thionyl chloride, triphenyl phosphin/carbontetrachloride, bromine, hydrobromic acid, triphenyl phosphin/carbontetrabromide, phosphor tribromide and others described in the literature, for example, in Chem. Ber. 123(12), 2387-94, 1990; J. Am. Chem. Soc, 111(9), 3363-3368, 1989; J. Org.
  • a suitable halogenation agent such as thionyl chloride, triphenyl phosphin/carbontetrachloride, bromine, hydrobromic acid, triphenyl phosphin/carbontetrabromide, phosphor tribromide and others described in the literature, for example, in Chem. Ber. 123
  • reaction steps A, B and B1 may be carried out as described in Higgins et al., J.
  • Reaction step A is preferably carried out in an organic solvent such as dichloromethane, chlorofom, carbontetrachloride or mixtures thereof as reaction medium.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range.
  • the optimum conditions for a given reaction may be determined by conventional methods known to those skilled in the art.
  • Preferred reaction temperatures are from -10°C to +30 °C, preferably from 0°C to 25 °C, more preferably from 0 °C to 10°C.
  • Suitable reaction times vary from a few minutes to several hours, preferably from 3 to 8 hours.
  • Reaction step B is preferably carried out by dissolving the educt in a suitable reaction medium, preferably a linear ether such as diethylether, or a cyclic ether, such as tetrahydrofuran, 1 ,4-dioxane or 1 ,1-dimethoxyethan, and in the presence of an aqueous solution of a base, preferably selected from the group consisting of an alkali metal such as lithium, sodium, or potassium, under vigorous stirring.
  • a suitable reaction medium preferably a linear ether such as diethylether, or a cyclic ether, such as tetrahydrofuran, 1 ,4-dioxane or 1 ,1-dimethoxyethan
  • a base preferably selected from the group consisting of an alkali metal such as lithium, sodium, or potassium, under vigorous stirring.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range.
  • the optimum reaction conditions for a given reaction may be determined by conventional methods known to those skilled in the art.
  • Preferred reaction temperatures range from 10°C to the boiling point of the reaction mixture, preferably from 15°C to 25 °C.
  • Suitable reaction times vary from a few minutes to several hours, preferably from 3 to 8 hours
  • Reaction step B1 is preferably carried out in the presence of an oxidizing agent such as peracetic acid, m-chloro perbenzoic acid, N-Bromsuccinimide or the like.
  • an oxidizing agent such as peracetic acid, m-chloro perbenzoic acid, N-Bromsuccinimide or the like.
  • the 3-azetidinol compound is obtained by carrying out reaction step (c) according to the methods described in the literature publications of M.E. Jung, J. Org. Chem., 1991 , 56(24), 6729-6730; V.R. Gaertner, J. Org. Chem., 1967, 32, 2972, Katrizky et al., J. Heterocycl. Chem. 1994, 271-275, P.R. Dave et al, J. Org. Chem., 1996, 61 (16), 5453 and US 5,073,646.
  • the corresponding descriptions are incorporated by reference and form part of the present disclosure.
  • reaction steps A2, B2, C2a and C2b may be carried out according to conventional methods well known to those skilled in the art.
  • Step A2 is for example described in Hajipour et al., Synth. Commun. 1999, 29(10), 1697-1701 , A. Sasse et al., Arch. Pharm., 2001 , 334(2), 45-52.
  • Step B2 is for example described in the publication of Fernandez et al., Synthesis 2001 , (2), 239-242; Baruah et al., Synlett, 1999, (4), 409-410.
  • Steps C2a and C2b are for example disclosed in the publications of M. Grisar et al., J. Med.
  • Another aspect the present invention is a process for the preparation of substituted azetidine compounds of general formula I given above and corresponding stereoisomers thereof, according to which at least one compound of general formula
  • R and R 2 have the meaning given above and Y represents a halogen atom, preferably a chlorine atom or a bromine atom, is reacted with at least one compound of general formula VI,
  • azetidine compound(s) optionally in form of a salt, wherein R 3 , R 4 and R 5 have the meaning given above, in a suitable reaction medium, optionally in the presence of a base, and the resulting azetidine compound(s) is/are optionally purified and/or optionally isolated.
  • the compounds of general formula (Va) may, for example, be obtained according to step A3 of scheme 4 by reduction of a corresponding ketone compound with a suitable reducing agent such as sodium borohydride in a suitable reaction medium such as alcohol, preferably methanol, whereby the reaction temperature is preferably kept in the range of 0°C and the boling point of the reaction medium.
  • a suitable reducing agent such as sodium borohydride
  • a suitable reaction medium such as alcohol, preferably methanol
  • the compounds of general formula (Va) may, for example, also be obtained according to step B3 of scheme 4 by a Grignard reaction in a suitable inert reaction medium such as diethylether or tetrahydrofuran, whereby the reation temperature is preferably kept in the range of 0 °C and the boiling point of the reaction medium.
  • a suitable inert reaction medium such as diethylether or tetrahydrofuran
  • Reaction step C3 of scheme 4, in which X represents a halogen atom, preferably a chlorine or bromine atom, may be carried out using a suitable halogenating agent such as hydrobromic acid, thionyl bromide, thionyl chloride, acetyl bromide, in a suitable reaction medium such as acetic acid, benzene, toluene, dichloromethane or chloroform, whereby the reaction temperature is preferably kept in the range of 0°C to the boling point of the reaction medium.
  • a suitable halogenating agent such as hydrobromic acid, thionyl bromide, thionyl chloride, acetyl bromide
  • a suitable reaction medium such as acetic acid, benzene, toluene, dichloromethane or chloroform
  • the reaction of at least one compound of general formula V given above with at least one compound of general formula VI may preferably be carried out in an inert reaction medium, whereby acetonitrile, tetrahydrofuran or mixtures thereof are preferred.
  • Suitable bases include organic bases such as triethylamine and inorganic bases such as carbonates of alkali metals, preferably potassium carbonate, or potassium iodide.
  • the reaction temperature is preferably in the range of ambient temperature to the boling point of the reaction medium. The reaction times may vary over a broad range.
  • the compounds of general formula VI may be prepared from the corresponding substituted benzhydrylazetidine compounds of general formula VII,
  • compounds of general formula VI are preferably isolated in form of a corresponding salt such as a hydrochloride or hydrobromide salt.
  • the compounds of general formula VII may be prepared according to the methods described, for example, in US 5,073,646 and J. Frigola, J. Med. Chem., 1993, 36, 801-810.
  • the compounds of general formula VI are usually obtained in form of a mixture of diastereoisomers.
  • the respective enantiomers may be obtained by racemic resolution with HPLC using chiral columns or by crystallization with chiral derivatives obtained from the reaction of the corresponding racemate with chiral agents as described in the publication of J. Frigola, J. Med. Chem. 1994, 37, 4195- 4210 and J. Frigola, J. Med. Chem., 1995, 38, 1203-1215.
  • the corresponding enantiomers may also be obtained by asymmetric epoxidation in a corresponding reaction as described in scheme 2, which is carried out according to the method described in the publication of Sharpless et al., J. Am. Chem. Soc, 1980, 102, 5974- 5976; J. A. Marshall et al., Org. Lett., 2000 2(18), 2897-2900 using tert.-Butyl hydroperoxide in the presence of titanium isopropoxide and diethyl or diisopropyl tartrate as oxidant.
  • substituted azetidine compounds of general formula (I) themselves are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractunalized crystallization with chiral reagents. It is also possible to obtain pure stereoisomers via stereoselective synthesis.
  • Substituted azetidine compounds of general formula I which comprise nitrogen-atom containing saturated, unsaturated or aromatic rings may also be obtained in the form of their N-oxides by methods well known to those skilled in the art.
  • the present invention also provides a process for the preparation of salts of substituted azetidine compounds of general formula (I), stereoisomers thereof or N-oxides thereof, wherein at least one compound of general formula (I) having at least one basic group is reacted with at least one inorganic and/or organic acid, preferably in the presence of a suitable reaction medium.
  • Suitable reaction media include, for example, any of the ones given above.
  • Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid
  • suitable organic acids are e.g. citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.
  • the present invention also provides a process for the preparation of salts of substituted azetidine compounds of general formula (I), stereoisomers thereof or N-oxides thereof, wherein at least one compound of general formula (I) having at least one acidic group is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium.
  • suitable bases are e.g. hydroxides, carbonates or alkoxides, which include suitable cations, derived e.g. from alkaline metals, alkaline earth metals or organic cations, e.g.
  • Suitable reaction media are, for example, any of the ones given above.
  • Solvates, preferably hydrates, of the substituted azetidine compounds of general formula (I), of corresponding stereoisomers, corresponding N-oxides thereof, or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art.
  • the purification and isolation of the inventive substituted azetidine compounds of general formula (I), of a corresponding stereoisomer, or salt, or solvate or any intermediate thereof may, if required, be carried out by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization.
  • substituted azetidine compounds of general formula (I), their N-oxides, their stereoisomers, corresponding salts thereof and corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances for the preparation of medicaments.
  • an other aspect of the present invention is a medicament comprising at least one substituted azetidine compound of general formula I given above including the afore disclaimed compounds, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients.
  • Said medicament may comprise any combination of one or more of the substituted azetidine compounds of general formula I given above, stereoisomers thereof, corresponding N-oxides thereof, physiologically acceptable salts thereof or physiologically acceptable solvates thereof.
  • said medicament is suitable for the modulation (regulation) of cannabinoid-receptors, preferably cannabinoid 1 (CB-i) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
  • cannabinoid-receptors preferably cannabinoid 1 (CB-i) receptors
  • said medicament is suitable for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of psychosis, schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, inflammation, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, cancer, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorragic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type II diabetus mellitus (non-insuline dependent diabetes mellitus), memory disorders, pruritus, alcoholism, drug addiction, medicament
  • the inventive medicament is suitable for the prophylaxis and/or treatment of pain, of food intake disorders, preferably bulimia, anorexia, cachexia, obesity or type II diabetus mellitus (non-insuline dependent diabetes mellitus), preferably diabetes, psychosis, alcoholism, drug addiction and/or medicament addiction, preferably drug addiction, diarrhea and/or pruritus.
  • food intake disorders preferably bulimia, anorexia, cachexia, obesity or type II diabetus mellitus (non-insuline dependent diabetes mellitus), preferably diabetes, psychosis, alcoholism, drug addiction and/or medicament addiction, preferably drug addiction, diarrhea and/or pruritus.
  • the inventive medicament is suitable for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of obesity, psychosis and/or drug addiction.
  • Another aspect of the present invention is the use of at least one substituted azetidine compound of general formula I including the afore disclaimed compounds, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB ⁇ ) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of
  • the medicament according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art.
  • the composition of the medicament may vary depending on the route of administration.
  • the medicament of the present invention may for example be administered parentally in combination with conventional injectable liquid carriers, such as water or suitable alcohols.
  • conventional pharmaceutical excipients for injection such as stabilizing agents, solubilizing agents, and buffers, may be included in such injectable compositions.
  • These medicaments may for example be injected intramuscularly, intraperitoneally, or intravenously.
  • Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form. These compositions may contain conventional ingredients such as binding agents, fillers, lubricants, and acceptable wetting agents.
  • the compositions may take any convenient form, such as tablets, pellets, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powdered forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or retarded release.
  • liquid oral forms for administration may also contain certain additives such as sweeteners, flavoring, preservatives, and emulsifying agents.
  • Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Such liquid compositions may be conveniently encapsulated in e.g., gelatin capsules in a unit dosage amount.
  • the compositions of the present invention may also be administered topically or via a suppository.
  • the daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth.
  • the daily dosage for humans may preferably be in the range froml to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of active substance to be administered during one or several intakes per day.
  • Substances with affinity for cannabinoid receptors are known to produce a wide range of pharmacological effects. It is also known that intravenous administration of a substance with affinity for cannabinoid receptors in mice produces analgesia , hypothermia, sedation and catalepsy. Individually, none of these effects can be considered as proof that a tested substance has affinity for cannabinoid-receptors, since all of these effects are common for various classes of centrally active agents. However, substances, which show all of these effects, i.e. substances that are active in this so-called tetrad model are considered to have affinity for the cannabinoid receptors. It has further been shown that cannabinoid receptor antagonists are higly effective in blocking the effects of a cannabinoid agonist in the mouse tetrad model.
  • mice with a weight of 20-30 g Male NMRI mice with a weight of 20-30 g (Harlan, Barcelona, Spain) are used in all of the following experiments.
  • mice are acclimatized to the experimental setting.
  • Pre-Treatment control values are determined for analgesia hot plate latency (in seconds), rectal temperature, sedation and catalepsy.
  • the mice are injected intravenously with the substance to be tested or the vehicle alone. 15 minutes after injection, latency in hot plate analgesia is measured. Rectal temperature, sedation and catalepsy are measured 20 minutes after injection.
  • the hot plate analgesia is determined according to the method described in Woolfe D. et al. butThe evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. Pharmacol. Exp. Ther. 80, 300-307,1944. The respective description is hereby incorporated by reference and forms part of the present disclosure.
  • mice are placed on a hot plate (Harvard Analgesimeter) at 55 ⁇ 0.5 °C until they show a painful sensation by licking their paws or jumping and the time for these sensations to occur is recorded. This reading is considered the basal value (B).
  • B basal value
  • PC cut-off time
  • mice Fifteen minuts after the administration of the substance to be tested, the mice are again placed on the hot plate and the afore described procedure is repeated. This period is called the post-treatment reading (PT).
  • PT post-treatment reading
  • the degree of analgesia is calculated from the formula :
  • % MPE of Analgesia ( PT- B) / (PC-B) x 100
  • Sedation and ataxia is determined according to the method described in Desmet L. K. C. et al. perennial Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", Arzneim. -Forsch. (Frug Res) 25, 9, 1975.
  • the respective description is hereby incorporated by reference and forms part of the present disclosure.
  • the chosen scoring system is
  • the percentage of sedation is determined according to the formula:
  • % of sedation arithmetic mean / 3 X 100
  • the base-line rectal temperatures are determined with a thermometer (Yello Springs Instruments Co., Panlabs) and a thermistor probe inserted to 25mm before the administration of the substance to be tested. Rectal temperature is again measured 20 minutes after the administration of the substances to be tested. The temperature difference is calculated for each animal, whereby differences of >-2 °C are considered to represent activity.
  • Catalepsy is determined according to the method described in Alpermann H. G. et al. -Pharmacological effets of Hoe 249: A new potential antidepressant", Drugs Dev. Res. 25, 267-282. 1992. The respective description is hereby incorporated by reference and forms part of the present disclosure.
  • the cataleptic effect of the substance to be tested is evaluated according to the duration of catalepsy, whereby the animals are placed head downwards with their kinlegs upon the top of the wooden block.
  • the chosen scoring system is:
  • the percentage of catalepsy is determined according ot the following formula:
  • % Catalepsy arithmetic mean / 6 X 100
  • the etheric layer of the first extraction was acidified with dilute 5 % (volume/volume) acetic acid, the acidic layer alkalinized with sodium hydroxide and extracted wilh dichloromethane, to yield 6.3 g of the compound giving a total of 16.3 g (70% of theory) of trans-3-amino-1-diphenylmethyl-2-methylazetidine having a melting point of 68-69° C.
  • the enantiomer (2S, 3R)-1-diphenylmethyl-2-methyl-3-methylsulphonyloxyazetidine was obtained by the same procedure as described above for the preparation of the trans-racemate but using (2S, 3R)-1-diphenylmethyl-3-hydroxy-2-methylazetidine.
  • the compound (2S, 3R)-1-diphenylmethyl-3-hydroxy-2-methylazetidine was obtained via the optical resolution of trans-1 -diphenylmethyl-3-hydroxy-2-methylazetidine with (+)-(1S)-camphersulfonic acid, as described in the literature publication of J. Frigola et al., J. Med. Chem., 1995, 38, 1203-1215.
  • the crude material is dissolved in 15 ml of ethanol, and an ethanolic solution saturated with hydrochloride gas is added to precipitate the corresponding hydrochloride salt, which is filtered off and washed with diethylether to yield 3.95 g (yield 85% of theory) of the hydrochloride salt having a melting point of 163 - 166 °C.
  • This compound was obtained via the hydrolysis of the ester prepared according to step (1c) given above, which was dissolved in ethanol comprising 10 % by weight of sodium hydroxide. The reaction mixture was kept at room temperature (approximately 25 °C) overnight. 1-[Bis-(4-chloro-phenyi)-methyl]-2-methyl-azetidin- 3-ol was obtained in a yield of 89%.
  • inventive azetidine compounds act as cannabinoid receptor antagonists, particularly for the CB-i-receptors.
PCT/EP2005/001658 2004-02-17 2005-02-16 Substituted azetidine compounds, their preparation and use as medicaments WO2005077897A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
RU2006133258/04A RU2006133258A (ru) 2004-02-17 2005-02-16 Замещенные азетидиновые производные, их получение и применение в качестве лекарственных средств
CA002556565A CA2556565A1 (en) 2004-02-17 2005-02-16 Substituted azetidine compounds, their preparation and use as medicaments
BRPI0507801-6A BRPI0507801A (pt) 2004-02-17 2005-02-16 compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
JP2006553539A JP2007522255A (ja) 2004-02-17 2005-02-16 置換アゼチジン化合物、その製造および医薬品としての使用
AU2005212835A AU2005212835A1 (en) 2004-02-17 2005-02-16 Substituted Azetidine compounds, their preparation and use as medicaments
EP05715383A EP1718609A1 (de) 2004-02-17 2005-02-16 Substituierte azetidinverbindungen, deren herstellung und deren verwendung als medikamente
IL177456A IL177456A0 (en) 2004-02-17 2006-08-10 Substituted azetidine compounds, their preparation and use as medicaments
US11/505,463 US20070066587A1 (en) 2004-02-17 2006-08-17 Substituted azetidine compounds, their preparation and use as medicaments
NO20064078A NO20064078L (no) 2004-02-17 2006-09-11 Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES200400379 2004-02-17
ES200400379A ES2244314B1 (es) 2004-02-17 2004-02-17 Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos.
US10/804,558 2004-03-19
US10/804,558 US20050187208A1 (en) 2004-02-17 2004-03-19 Substituted Azetidine compounds, their preparation and use as medicaments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/505,463 Continuation-In-Part US20070066587A1 (en) 2004-02-17 2006-08-17 Substituted azetidine compounds, their preparation and use as medicaments

Publications (1)

Publication Number Publication Date
WO2005077897A1 true WO2005077897A1 (en) 2005-08-25

Family

ID=34863169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001658 WO2005077897A1 (en) 2004-02-17 2005-02-16 Substituted azetidine compounds, their preparation and use as medicaments

Country Status (9)

Country Link
EP (1) EP1718609A1 (de)
JP (1) JP2007522255A (de)
KR (1) KR20060124756A (de)
AU (1) AU2005212835A1 (de)
BR (1) BRPI0507801A (de)
CA (1) CA2556565A1 (de)
NO (1) NO20064078L (de)
RU (1) RU2006133258A (de)
WO (1) WO2005077897A1 (de)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007169270A (ja) * 2005-11-25 2007-07-05 Tanabe Seiyaku Co Ltd 医薬組成物
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
WO2009021740A2 (de) 2007-08-15 2009-02-19 Sanofis-Aventis Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2928149A1 (fr) * 2008-02-29 2009-09-04 Sanofi Aventis Sa Composes derives d'azetidines, leur preparation et leur application en therapeutique
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
FR2946650A1 (fr) * 2009-06-16 2010-12-17 Sanofi Aventis Esters derives d'azetidines, leur preparation et leur application en therapeutique.
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013001505A3 (en) * 2011-06-29 2013-03-07 Adamed Sp. Z O.O. Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
EP2754653A2 (de) * 2011-09-05 2014-07-16 Korea Institute of Science and Technology Azetidinderivat und antidepressive zusammensetzung damit
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406112A1 (de) * 1989-06-29 1991-01-02 Laboratorios Del Dr. Esteve, S.A. 1-Benzhydrylazetidine, deren Herstellung und Verwendung als Zwischenprodukte zur Herstellung von Verbindungen mit antimikrobieller Wirkung
WO2001064633A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
WO2003020314A1 (fr) * 2001-08-29 2003-03-13 Aventis Pharma S.A. Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau
WO2003053431A2 (fr) 2001-12-21 2003-07-03 Aventis Pharma S.A. Compositions pharmaceutiques a base de derives d'azetidine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406112A1 (de) * 1989-06-29 1991-01-02 Laboratorios Del Dr. Esteve, S.A. 1-Benzhydrylazetidine, deren Herstellung und Verwendung als Zwischenprodukte zur Herstellung von Verbindungen mit antimikrobieller Wirkung
US5073646A (en) 1989-06-29 1991-12-17 Laboratorios Del Dr. Esteve, S.A. Substituted 1-diphenylmethyl azetidines
WO2001064633A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
WO2003020314A1 (fr) * 2001-08-29 2003-03-13 Aventis Pharma S.A. Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau
WO2003053431A2 (fr) 2001-12-21 2003-07-03 Aventis Pharma S.A. Compositions pharmaceutiques a base de derives d'azetidine

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
A. C. HOWLETT ET AL.: "International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors", PHARMACOL REV, vol. 54, 2002, pages 161 - 202
A. SASSE ET AL., ARCH. PHARM., vol. 334, no. 2, 2001, pages 45 - 52
ALPERMANN H. G. ET AL.: "Pharmacological effets of Hoe 249: A new potential antidepressant", DRUGS DEV. RES., vol. 25, 1992, pages 267 - 282
AXENROD ET AL., TETRAHEDRON LETT., 1993, pages 6677 - 6680
BARUAH ET AL., SYNLETT, no. 4, 1999, pages 409 - 410
BULL. SOC. CHIM. FRANCE, vol. 132, no. 5-6, 1995, pages 522 - 30
CATALYSIS LETTERS, vol. 62, no. 2-4, 1999, pages 175 - 177
CHEM. BER., vol. 123, no. 12, 1990, pages 2387 - 94
CONSROE; SANDYK: "Neurobiology and Neurophysiology", vol. 459, 1992, CRC PRESS, article "Marijuana/Cannabinoids"
DAVID R. COMPTON ET AL.: "In-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A) :Inhibition of Tetrahvdrocannbinol- induced Responses and Apparent Aaonist Activity", J. PHARMACOL. EXP. THER., vol. 277, no. 2, 1996, pages 586 - 594
DAVID R. COMPTON ET AL.: "In-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A) Inhibition of Tetrahydrocannbinol- induced Responses and Apparent Agonist Activity", J. PHARMACOL EXP THER., vol. 277, no. 2, 1996, pages 586 - 594
DEJAEGHER ET AL., SYNLETT., 2002, pages 113 - 115
DESMET L. K. C. ET AL.: "Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", ARZNEIM. -FORSCH. (FRUG RES), vol. 25, 1975, pages 9
FARMACO, vol. 44, no. 12, 1989, pages 1167 - 91
FERNANDEZ ET AL., SYNTHESIS, no. 2, 2001, pages 239 - 242
FRIGOLA J ET AL: "7-Azetidinylquinolones as Antibacterial Agents. 2. Synthesis and Biological Activity of 7-(2,3-Disubstituted-1-azetidinyl)-4-oxoquino line- and -1,8-naphthyridine-3-carboxylic Acids. Properties and Structure-Activity Relationships of Quinolones with an Azetidine Moiety", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 24, 1994, pages 4195 - 4210, XP002115349, ISSN: 0022-2623 *
FRIGOLA J ET AL: "7-Azetidinylquinolones as Antibacterial Agents. 3. Synthesis, Properties and Structure-Activity Relationships of the Stereoisomers Containing a 7-(3-Amino-2-methyl-1-azetidinyl) Moiety", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 7, 1995, pages 1203 - 1215, XP002115345, ISSN: 0022-2623 *
HAJIPOUR ET AL., SYNTH. COMMUN., vol. 29, no. 10, 1999, pages 1697 - 1701
HETEROCYCLES, vol. 32, no. 5, 1991, pages 965 - 73
HIGGINS ET AL., J. HETEROCYCLIC CHEM., vol. 8, 1971, pages 1059 - 1062
HOLLISTER, PHARM. REV., vol. 38, 1986, pages 1 - 20
J. A. MARSHALL ET AL., ORG. LETT., vol. 2, no. 18, 2000, pages 2897 - 2900
J. AM. CHEM. SOC., 2001, pages 12168 - 12175
J. AM. CHEM. SOC., vol. 111, no. 9, 1989, pages 3363 - 3368
J. FRIGOLA ET AL., J. MED. CHEM., vol. 38, 1995, pages 1203 - 1215
J. FRIGOLA, J. MED. CHEM., vol. 36, 1993, pages 801 - 810
J. FRIGOLA, J. MED. CHEM., vol. 37, 1994, pages 4195 - 4210
J. FRIGOLA, J. MED. CHEM., vol. 38, 1995, pages 1203 - 1215
J. MED. CHEM., vol. 33, no. 3, 1990, pages 908 - 18
J. NATURAL PRODUCTS, vol. 65, no. 6, 2002, pages 902 - 908
J. ORG. CHEM., vol. 63, no. 25, 1998, pages 9565 - 68
J. ORG. CHEM., vol. 64, no. 7, 1999, pages 2582 - 2589
KATRITZKY ET AL., J. HETEROCYCL. CHEM., 1994, pages 271 - 275
KATRIZKY ET AL., J. HETEROCYCL. CHEM., 1994, pages 271 - 275
M. GRISAR ET AL., J. MED. CHEM., 1973, pages 885
M.E. JUNG, J. ORG. CHEM., vol. 56, no. 24, 1991, pages 6729 - 6730
P.R. DAVE ET AL., J. ORG. CHEM., vol. 61, no. 16, 1996, pages 5453
RENY; SINGHA, PROG. DRUG. RES., vol. 36, 1991, pages 71 - 114
RUTH A. ROSS; HEATHER C. BROCKIE ET AL.: "Agonist-inverse agonist characterization at CB and CB2 cannabinoid receptors of L-759633, L759656 and AM630", BRITISH JOURNAL OF PHARMACOLOGY, vol. 126, 1999, pages 665 - 672
SHARPLESS ET AL., J. AM. CHEM. SOC., vol. 102, 1980, pages 5974 - 5976
SYNLETT., 1991, pages 783 - 784
SYNLETT., 1999, pages 1763 - 65
SYNTHESIS, vol. 8, 1989, pages 598 - 603
TETRAHEDRON LETT., vol. 43, no. 49, 2002, pages 8893 - 8896
TETRAHEDRON, vol. 40, no. 7, 1984, pages 1195 - 1198
V.R. GAERTNER, J. ORG. CHEM., vol. 32, 1967, pages 2972
WOOLFE D. ET AL.: "The evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. PHARMACOL. EXP. THER., vol. 80, 1944, pages 300 - 307

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
US7906503B2 (en) 2003-06-11 2011-03-15 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
JP2007169270A (ja) * 2005-11-25 2007-07-05 Tanabe Seiyaku Co Ltd 医薬組成物
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2009021740A2 (de) 2007-08-15 2009-02-19 Sanofis-Aventis Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2009118473A3 (fr) * 2008-02-29 2009-11-19 Sanofi-Aventis Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
WO2009118473A2 (fr) 2008-02-29 2009-10-01 Sanofi-Aventis Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
FR2928149A1 (fr) * 2008-02-29 2009-09-04 Sanofi Aventis Sa Composes derives d'azetidines, leur preparation et leur application en therapeutique
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
FR2946650A1 (fr) * 2009-06-16 2010-12-17 Sanofi Aventis Esters derives d'azetidines, leur preparation et leur application en therapeutique.
WO2010146299A1 (fr) * 2009-06-16 2010-12-23 Sanofi-Aventis Esters derives d'azetidines, leur preparation et leur application en therapeutique comme modulateurs des recepteurs cannabinoides
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013001505A3 (en) * 2011-06-29 2013-03-07 Adamed Sp. Z O.O. Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
EP2754653A2 (de) * 2011-09-05 2014-07-16 Korea Institute of Science and Technology Azetidinderivat und antidepressive zusammensetzung damit
EP2754653A4 (de) * 2011-09-05 2015-02-18 Korea Inst Sci & Tech Azetidinderivat und antidepressive zusammensetzung damit
US9120771B2 (en) 2011-09-05 2015-09-01 Korea Institute Of Science And Technology Azetidine derivative and antidepressant composition including the same

Also Published As

Publication number Publication date
AU2005212835A1 (en) 2005-08-25
BRPI0507801A (pt) 2007-07-10
CA2556565A1 (en) 2005-08-25
KR20060124756A (ko) 2006-12-05
EP1718609A1 (de) 2006-11-08
NO20064078L (no) 2006-09-11
JP2007522255A (ja) 2007-08-09
RU2006133258A (ru) 2008-04-10

Similar Documents

Publication Publication Date Title
WO2005077897A1 (en) Substituted azetidine compounds, their preparation and use as medicaments
US7524868B2 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
UA73554C2 (en) A pharmaceutical composition containing azetidine derivatives, azetidine derivatives and preparation thereof
US20070066587A1 (en) Substituted azetidine compounds, their preparation and use as medicaments
EP1757587A1 (de) Substituierte Pyrazolinderivate, ihre Herstellung und Verwendung als Arzneimittel
EP1743890A1 (de) 4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente.
WO2006069807A1 (en) Substituted phenyl-piperazine compounds, their preparation and use in medicaments
JP2008525388A (ja) カンナビノイドｃｂ１受容体アンタゴニストとしてのｎ−［（４，５−ジフェニル−３−アルキル−２−チエニル）メチル］アミン（アミド、スルホンアミド、カルバミン酸及び尿素）誘導体
WO2007017124A1 (en) Amorphous phase of a substituted pyrazoline, its preparation and use as medicament
WO2007009705A1 (en) (rac)-n-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydr0-1h-pyrazole-3-carboxamide hydrates
WO2007017126A2 (en) POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
EP1743892A1 (de) Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament
EP1743888A1 (de) Carbonyl-substituierte Pyrazolin-Verbindungen zur Verwendung als CB1-Rezeptor Modulatoren
US7790727B2 (en) Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
JP2008088057A (ja) Ｎ−置換−ｎ−（４−ピペリジニル）アミド誘導体
EP1743894A1 (de) Heterocyclyl-substituierte Pyrazolinverbindungen, ihre Herstellung und Verwendung als Medikamente
MXPA06009336A (es) Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos
US20090149472A1 (en) Salts of substitutted pyrazoline compounds, their preparation and use and medicaments
MX2011001669A (es) Compuestos polisustituidos de azetidinas, su preparacion y su aplicacion en terapeutica.
EP1749821A1 (de) Salze von substituierten Pyrazolin Derivaten, ihre Herstellung und Anwendung als Arzneimittel
MXPA06009334A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743887A1 (de) Thiocarbonyl-Substituierte Pyrazolin-Verbindungen zur Verwendung als CB1-Rezeptor Modulatoren

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 177456

Country of ref document: IL

Ref document number: 4609/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/06732

Country of ref document: ZA

Ref document number: 200606732

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2556565

Country of ref document: CA

Ref document number: PA/a/2006/009336

Country of ref document: MX

Ref document number: 549201

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006553539

Country of ref document: JP

Ref document number: 11505463

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005212835

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005715383

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005212835

Country of ref document: AU

Date of ref document: 20050216

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005212835

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067018702

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006133258

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580011514.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005715383

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067018702

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 11505463

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0507801

Country of ref document: BR